SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that new consensus data from a survey of leading breast cancer oncologists in Europe suggest the importance of gene expression profile (GEP) testing in guiding treatment decisions for women with early-stage breast cancer. The findings, from the PROCURE study, were presented today at the European Society of Medical Oncology (ESMO) Breast Cancer 2022, taking place May 3-5 in Berlin, Germany.
The PROCURE study utilized Delphi methodology to generate consensus regarding the clinical utility of GEP tests, including Veracyte’s Prosigna Breast Cancer Assay, in breast cancer treatment. A scientific committee of eight breast cancer experts developed a questionnaire, which was used to survey 133 specialists from 11 European countries. Consensus was achieved when at least 70 percent of respondents agreed on a topic. Among the findings:
- 88 percent of participants give importance to GEP prognostic results when deciding on chemotherapy usage in the adjuvant setting for early-stage breast cancer patients whose disease has not spread to the lymph nodes;
- 75 percent also consider it important when deciding on chemotherapy in the adjuvant setting in early-stage patients with 1 to 3 positive lymph nodes;
- 76 percent of participants agreed on the clinical utility of molecular subtype information from GEP testing to assess likelihood of disease recurrence among early-stage breast cancer patients who are hormone-receptor positive; and
- 75 percent think the use of molecular subtype information is useful to identify such patients who may safely avoid chemotherapy.
“Our findings show that use of gene expression profile tests has become standard of care among physicians in Europe to help guide treatment decisions for women with early-stage breast cancer,” said Giuseppe Curigliano, M.D., Ph.D., professor of medical oncology at the University of Milano and the head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, who presented the study findings. “We also found that physicians agree on the value of molecular subtype information, a more recent advance in such tests, to help inform treatment for individual patients.”
Also among the findings, 67 percent of respondents believe that GEP tests can help physicians determine the most appropriate type of chemotherapy treatment.
“While a large-scale, prospective trial to determine such predictive information from GEP testing would be valuable, our findings suggest more education is needed among breast cancer specialists regarding the role that GEP tests play today,” said Dr. Curigliano.
“We believe the PROCURE study will provide much-needed clarity to breast cancer clinicians and their patients about the clinical utility of GEP testing,” Kelly Marcom, M.D., Veracyte’s medical director for breast cancer. “We’re grateful for the opportunity to sponsor this important study and to demonstrate our commitment to the global breast cancer community.”
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the ten most prevalent cancers as defined by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to our best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, our statements associated with study data related to our Prosigna Breast Cancer Assay. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to our ability to launch, commercialize and receive reimbursement for our products and our ability to successfully integrate our business deals and execute on our business plans. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed on February 28, 2022 and on our Quarterly Report to be filed with the SEC for the quarter ended March 31, 2022. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, Immunoscore, TMExplore, Brightplex, Immunosign, “Know by Design” and “More about You” are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.
